List of Excipients in Branded Drug SUNITINIB MALATE

Generic Drugs Containing SUNITINIB MALATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	sunitinib malate	0093-8199	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	sunitinib malate	0093-8199	D&C RED NO. 28
Teva Pharmaceuticals USA Inc	sunitinib malate	0093-8199	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	sunitinib malate	0093-8199	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in SUNITINIB MALATE?

# Of NDCs	Excipient
1	AMMONIA
1	BUTYL ALCOHOL
9	CROSCARMELLOSE SODIUM
2	D&C RED NO. 28

Sunitinib Malate Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Sunitinib malate is an established oral oncology product with a mature generic market, but excipient suppliers and formulation developers still have opportunities in bioequivalence-enabling systems, manufacturing efficiency, capsule-shell differentiation, pediatric delivery, and global-market compliance. The reference product, Sutent, uses a relatively conventional hard-gelatin capsule formulation containing mannitol, croscarmellose sodium, povidone, and magnesium stearate, with colorants in the capsule shell [1].

The strongest commercial opportunities are unlikely to come from basic substitution of one common excipient for another. They are more likely to arise from differentiated excipient systems that improve powder flow, content uniformity, dissolution robustness, stability, or patient acceptability without changing the approved dosage form.

What is sunitinib malate and how is it formulated?

Sunitinib malate is the malate salt of sunitinib, a multitargeted tyrosine kinase inhibitor. Sutent is approved in the United States for gastrointestinal stromal tumor after disease progression or intolerance to imatinib, advanced renal cell carcinoma, and unresectable or metastatic pancreatic neuroendocrine tumors [1].

Reference-product composition

The U.S. prescribing information identifies the following inactive ingredients for Sutent capsules:

Formulation element	Reference-product component	Functional role
Diluent	Mannitol	Bulking agent and powder carrier
Disintegrant	Croscarmellose sodium	Promotes capsule-fill dispersion
Binder	Povidone	Improves powder cohesion and granulation behavior
Lubricant	Magnesium stearate	Reduces tooling and capsule-fill friction
Capsule shell	Gelatin	Dosage-form shell
Opacifier/colorants	Titanium dioxide and iron oxides	Identification and light protection

Sunitinib malate is supplied as an immediate-release capsule. The product can be administered with or without food, and the labeled strengths are 12.5 mg, 25 mg, 37.5 mg, and 50 mg [1].

The relatively low drug load in the 12.5 mg and 25 mg strengths makes blend uniformity a central formulation issue. A formulation that performs adequately at 50 mg may not transfer directly to the lower strengths without changes in particle-size distribution, premixing, geometric dilution, or carrier selection.

What excipient properties matter most for sunitinib malate?

Sunitinib malate formulation development is driven by dose uniformity, dissolution control, powder handling, and stability rather than by a need for a complex modified-release system.

Solubility and dissolution

Sunitinib is a weakly basic, low-solubility compound whose dissolution can vary with pH. The malate salt improves handling and aqueous behavior relative to the free base, but formulation performance remains sensitive to particle size, wetting, disintegration, and the microenvironment around the drug.

Relevant excipient functions include:

• Rapid wetting and dispersion of the drug particles.
• Consistent capsule rupture and powder deaggregation.
• Control of hydrophobic lubricant exposure.
• Maintenance of dissolution across pH conditions.
• Reduction of batch-to-batch variability in low-dose blends.

Croscarmellose sodium is a logical disintegrant for immediate-release capsules. Alternative superdisintegrants, including crospovidone and sodium starch glycolate, may create opportunities for formulation differentiation, but substitution must preserve dissolution and bioequivalence.

Powder flow and content uniformity

Mannitol is attractive because it is chemically familiar, available in direct-compression and spray-dried grades, and suitable for low-dose formulations. Its commercial value increases when the selected grade improves:

• Flow through capsule-filling equipment.
• Segregation resistance.
• Low-dose blend uniformity.
• Moisture control.
• Scale-up from development to commercial equipment.

Co-processed mannitol-based excipients may reduce the need for separate binder or flow-aid additions. Such systems can simplify the bill of materials, but the developer must control particle-size distribution and density to avoid segregation from sunitinib malate.

Lubrication

Magnesium stearate remains a conventional choice, but its concentration and mixing time require control. Excessive lubrication can delay wetting and dissolution, while inadequate lubrication can produce weight variation, sticking, or equipment fouling.

Commercial opportunities exist for:

• Lower-lubricant formulations.
• Alternative lubricants such as sodium stearyl fumarate.
• Process designs that reduce lubricant residence time.
• Continuous blending systems with tighter mixing control.

A lubricant change may appear technically minor, but it can affect dissolution, capsule-filling behavior, and stability. It may also create a new formulation package for regulatory filing if the inactive-ingredient profile differs materially from the reference product.

What formulation patents protect sunitinib malate products?

The main historical intellectual-property protection for sunitinib centered on the active compound, salts, pharmaceutical compositions, and therapeutic uses. The reference product's commercial protection was associated with Pfizer's Sutent franchise and related patent and regulatory exclusivities rather than with a highly complex excipient platform.

Patent categories relevant to formulation developers

Patent category	Relevance to sunitinib malate
Compound patents	Protect the sunitinib chemical entity
Salt patents	May cover malate or other pharmaceutically acceptable salts
Pharmaceutical-composition patents	May cover dosage forms or compositions containing sunitinib
Method-of-use patents	Cover specified cancers, dosing regimens, or treatment methods
Manufacturing patents	May cover synthesis, crystallization, purification, or solid-state processing
Formulation patents	May cover excipient combinations, release profiles, or specialized delivery systems

The commercial freedom-to-operate analysis must distinguish between an excipient substitution and a claim that covers the finished composition irrespective of the specific excipient. A formulation using different mannitol or disintegrant grades may still fall within a broad composition claim. Conversely, a narrow excipient claim may be avoided through a non-infringing formulation redesign.

The original composition and method-of-use patents have largely reached or passed their ordinary U.S. patent terms, subject to patent-term adjustment, pediatric extensions, terminal disclaimers, and jurisdiction-specific rights. Current development decisions should therefore focus on surviving claims, Orange Book listings, ANDA certifications, litigation records, and foreign national-phase patents rather than on historical Sutent launch dates alone.

When did sunitinib malate lose exclusivity?

Sutent entered the U.S. market in 2006. Its regulatory and patent protection extended beyond the initial approval period, with generic competition emerging after expiration of key protections and associated litigation or settlement constraints.

Exclusivity timeline

Milestone	Date or period	Commercial significance
FDA approval of Sutent	January 2006	Established the reference product
Initial oncology launches	2006 onward	Created the originator market in GIST and RCC
pNET approval	2011	Expanded the labeled market
Pediatric exclusivity and patent-term effects	Early 2020s	Delayed or shaped generic entry
U.S. generic approvals	Early 2020s	Opened multisource competition
Current market	2020s	Price and share pressure from multiple generic suppliers

FDA records identify sunitinib malate capsules as an approved abbreviated-new-drug-application product category. Generic manufacturers have entered or pursued entry across the principal capsule strengths, with market availability varying by strength, supplier, and distribution channel [2].

What is the Orange Book status of sunitinib malate?

The Orange Book is the controlling source for listed patents, therapeutic-equivalence evaluations, and current reference-product information. Sutent is listed as the reference product for sunitinib malate capsules, while approved generic products may receive an “AB” therapeutic-equivalence rating when they satisfy FDA requirements for pharmaceutical and bioequivalence [2].

Orange Book analysis should examine:

1. Listed patents for each reference product strength and indication.
2. Patent expiration and pediatric-exclusivity dates.
3. Whether a generic applicant filed Paragraph III or Paragraph IV certifications.
4. Whether listed-use patents remain relevant to the proposed label.
5. Whether a patent dispute resulted in a settlement or launch restriction.

For sunitinib, the practical Orange Book risk is more limited than for many newer oncology products because the market has already moved into the generic phase. The remaining legal questions are product-specific and jurisdiction-specific, particularly for later-filed formulation or use patents.

Which companies are challenging or competing with Sutent?

Competition comes from generic capsule manufacturers rather than biosimilar developers. Sunitinib is a chemically synthesized small molecule, so it is not subject to the biosimilar pathway.

Competitive landscape

Potential commercial participants include:

• Generic pharmaceutical companies with approved or pending sunitinib malate ANDAs.
• Contract development and manufacturing organizations supporting capsule production.
• Regional manufacturers selling outside the United States.
• Specialty oncology distributors and hospital suppliers.
• Excipient suppliers offering direct-compression, low-moisture, or co-processed systems.

The relevant competitive variables are product availability, price, supply continuity, number of approved strengths, wholesaler access, and demonstrated dissolution consistency. A supplier with all four strengths and stable inventory can compete more effectively than a supplier offering only the 50 mg presentation.

What excipient strategies create commercial opportunities?

The most viable strategies are incremental and manufacturing-focused.

1. Low-dose blend-uniformity platform

A mannitol-based carrier system can be optimized for the 12.5 mg and 25 mg strengths. The platform may use controlled particle size, ordered mixing, or a co-processed carrier to reduce segregation.

Commercial value comes from:

• Improved content uniformity.
• Reduced rejection risk.
• Lower sampling burden.
• Easier scale-up.
• One platform across multiple strengths.

2. Dissolution-robust immediate-release system

A formulation using croscarmellose sodium, crospovidone, or a combination can target rapid and reproducible dissolution. The key is to control lubricant level, blend time, and drug particle size.

This approach may be useful where generic competition has already compressed price and a developer needs a manufacturing advantage rather than a new therapeutic claim.

3. Pediatric and swallowing-friendly presentations

Sunitinib is used in oncology settings where swallowing difficulty, dose adjustment, and treatment duration can create adherence problems. Commercial opportunities include:

• Sprinkle-compatible capsule contents, if supported by stability and labeling data.
• Smaller capsules for lower doses.
• Age-appropriate oral powder or suspension systems.
• Taste-masking technologies for liquid development.
• Flexible dose-combination packaging.

These products would require a regulatory strategy distinct from a conventional ANDA capsule. A new dosage form could require a 505(b)(2) application or another jurisdiction-specific pathway.

4. Capsule-shell differentiation

Sutent uses hard gelatin capsules with strength-specific color coding. Developers may consider hypromellose shells for vegetarian, religious, or regional-market requirements. The shell change must preserve moisture protection, mechanical performance, disintegration, and product identification.

Capsule-shell substitution is commercially relevant in markets where gelatin restrictions affect procurement or patient acceptance. It is usually a product-positioning opportunity rather than a strong standalone patent strategy.

5. Global excipient compliance

A global sunitinib product must account for regional restrictions on excipients, animal-derived gelatin, colorants, residual solvents, and elemental impurities. Excipient suppliers can create value through:

• Pharmacopeial compliance packages.
• TSE/BSE documentation for gelatin.
• Consistent global-grade supply.
• Nitrosamine-risk assessments.
• Extractables and leachables data for alternative shells.
• Regional regulatory support.

Supply qualification can be as important as formulation performance in oncology products, where shortages and treatment interruptions carry high commercial costs.

How strong is the sunitinib malate formulation patent estate?

The formulation estate is weaker as a barrier than the estates surrounding newer targeted oncology products with long-lived solid-state, delivery, or combination patents. Sunitinib's core commercial defense historically rested on active-ingredient and use protection.

A practical strength assessment is:

Estate component	Relative commercial strength
Core compound protection	Historical, largely expired or substantially eroded
Malate salt protection	Potentially relevant historically; requires claim-by-claim review
Conventional capsule formulation	Low to moderate barrier
Novel pediatric or liquid formulation	Potentially stronger if supported by new data
Manufacturing process	Moderate where difficult to reproduce or scale
Method-of-use claims	Potentially relevant in specialty indications
Excipient-specific claims	Narrow unless supported by unexpected performance

A new excipient patent is more defensible when it claims a defined composition tied to measurable performance, such as dissolution across specified pH conditions, improved stability, reduced impurity formation, or superior content uniformity. A claim covering the use of a routine grade of mannitol or magnesium stearate alone is less likely to create durable competitive protection.

What generic entry risks exist for sunitinib malate?

Generic entry risk is high in the United States because approved multisource products are available and the product is an immediate-release capsule with familiar excipients. Remaining risks are primarily commercial and operational.

Generic launch scenarios

Scenario	Likely market effect
One or two suppliers	Moderate price erosion; supply remains concentrated
Multiple suppliers across all strengths	Significant price compression
Hospital and specialty-pharmacy substitution	Faster reference-product share loss
Authorized generic or coordinated launch	Greater price pressure
Supply disruption at a major generic manufacturer	Temporary originator or competitor recovery
Differentiated pediatric or liquid product	Niche premium opportunity

Paragraph IV litigation is most relevant to any later entrant challenging a still-listed patent. For current capsule competition, the greater risk is the ordinary erosion of price and volume after generic entry. Settlement agreements, if any, must be reviewed in the relevant court docket and applicant-specific regulatory records.

What manufacturing and IP barriers affect commercial development?

Manufacturing barriers are manageable but not trivial. Sunitinib malate products require control of:

• Low-dose blend uniformity.
• Powder segregation.
• Capsule-fill weight.
• Drug particle-size distribution.
• Lubrication and dissolution.
• Moisture exposure.
• Capsule-shell integrity.
• Impurity and degradation profiles.

The most defensible commercial package combines a formulation advantage with a process advantage. Examples include a controlled-particle-size drug substance, a co-processed mannitol carrier, a validated low-shear blending process, and a capsule shell with documented moisture performance.

Geographic coverage also matters. U.S. FDA approval does not establish European, Japanese, Chinese, or emerging-market approval. Excipients acceptable in one market may require different documentation or may be restricted in another. Regional filings should therefore align the formulation, supplier qualification file, and impurity-control strategy from the outset.

How does sunitinib malate compare with newer oncology products?

Sunitinib has a more mature and commoditized formulation opportunity than newer oral kinase inhibitors.

Factor	Sunitinib malate	Newer oral kinase inhibitors
Dosage form	Immediate-release capsule	Capsule, tablet, or specialized delivery
Generic risk	High	Often lower before patent expiry
Excipient complexity	Moderate	Often moderate to high
Main formulation issue	Uniformity and dissolution	Solubility, food effect, stability, or delivery
Biosimilar pathway	Not applicable	Not applicable for small molecules
Premium excipient opportunity	Niche	Often broader before generic entry
Patent leverage	Mature and eroded	Frequently stronger and longer-lived

Sunitinib is therefore best approached as a cost-efficient, globally compliant, reliable capsule platform, with selective opportunities in pediatric delivery and manufacturing differentiation.

Key Takeaways

• Sutent uses a conventional immediate-release hard-gelatin capsule containing mannitol, croscarmellose sodium, povidone, and magnesium stearate.
• The principal technical risks are low-dose blend uniformity, powder segregation, dissolution consistency, lubrication, and moisture control.
• Generic competition is established, making cost, supply reliability, and strength coverage more important than basic formulation novelty.
• The most attractive excipient opportunities involve co-processed mannitol systems, dissolution-robust disintegrant platforms, alternative capsule shells, and pediatric delivery.
• Sunitinib is a small molecule, so biosimilar competition is not applicable.
• New patent value is more likely in a defined, data-supported formulation or manufacturing process than in routine excipient substitution.
• Orange Book and court-docket review remains necessary for applicant-specific Paragraph IV, settlement, and launch-status analysis.

FAQs About Sunitinib Malate Excipient Commercialization

Can sunitinib malate be formulated as a tablet instead of a capsule?

Yes. A tablet could be developed, but it would require demonstration of comparable performance and a suitable regulatory pathway. The tablet would need to address low-dose uniformity, dissolution, stability, and patient acceptability.

Is mannitol a strong excipient choice for sunitinib malate?

Mannitol is a practical choice because it supports low-dose capsule filling and is available in multiple pharmaceutical grades. Its value depends on particle size, flow, moisture behavior, and compatibility with the selected blending process.

Can hypromellose replace gelatin in sunitinib capsules?

Hypromellose can be considered as an alternative capsule-shell material. The developer must establish equivalent mechanical, disintegration, moisture, stability, and identification performance.

Does sunitinib malate require a biosimilar development strategy?

No. Sunitinib malate is a chemically synthesized small molecule. Competitors generally use an ANDA or another small-molecule generic pathway, not a biosimilar application.

Where is the strongest premium opportunity in the sunitinib malate market?

The strongest premium opportunity is likely in a differentiated pediatric or swallowing-friendly presentation supported by robust stability, dose flexibility, and regulatory exclusivity. Conventional adult capsules are more exposed to generic price competition.

References

1. U.S. Food and Drug Administration. (2023). Sutent (sunitinib malate) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, sunitinib malate products. https://www.accessdata.fda.gov/scripts/cder/daf/

4. National Library of Medicine. (2024). DailyMed: Sunitinib malate capsule labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. European Medicines Agency. (2006). Sutent: EPAR product information. https://www.ema.europa.eu/